Gilead's 3Q EPS Squeezed by Rising R&D and SG&A Expenses
Dow Jones04:47
Gilead's 3Q 2026 diluted EPS fell to $1.94 from $2.43 a year earlier as rising operating costs offset a 13% increase in total product sales to $8.3 billion. R&D expenses climbed to $1.6 billion from $1.3 billion, driven by higher employee-related and clinical materials costs. SG&A expenses also rose to $1.6 billion from $1.4 billion, reflecting increased HIV promotional activities, acquisition integration costs, and legal-related expenses. Net losses from equity securities in the current year compared with gains in the prior year further weighed on earnings
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments